S 2137

Pharmaceutical Market Access Act of 2003

Congress: 108 (2003–2005, Ended)
Chamber: Senate
Policy Area: Health
Introduced: Feb 26, 2004
Current Status: Sponsor introductory remarks on measure. (CR S8932-8933)
Latest Action: Sponsor introductory remarks on measure. (CR S8932-8933) (Sep 8, 2004)
Official Text: https://www.congress.gov/bill/108th-congress/senate-bill/2137

Sponsor

Name: Sen. Dorgan, Byron L. [D-ND]
Party: Democratic • **State:** ND • **Chamber:** Senate

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Daschle, Thomas A. [D-SD]	D · SD		Feb 26, 2004
Sen. McCain, John [R-AZ]	R · AZ		Feb 26, 2004
Sen. Snowe, Olympia J. [R-ME]	R · ME		Feb 26, 2004
Sen. Stabenow, Debbie [D-MI]	D · MI		Feb 26, 2004

Committee Activity

No committee referrals or activity are recorded for this bill.

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
108 S 1781	Related bill	**Oct 24, 2003:** Referred to the Committee on Health, Education, Labor, and Pensions by unanimous consent.
108 HR 2427	Related bill	**Jul 25, 2003:** Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Feb 26, 2004)

Pharmaceutical Market Access Act of 2003 (sic) - Amends the Federal Food, Drug and Cosmetic Act to direct the Secretary of Health and Human Services to promulgate regulations allowing qualifying individuals to import covered products (in addition to pharmacists and wholesalers, whom current law authorizes to import such products).

Amends provisions pertaining to record keeping regarding imported covered products. States that the Secretary shall not have to store records in cases in which qualifying individuals have imported a covered product.

Amends provisions regarding the testing of imported covered products. Declares that specified tests, including ones involving authenticity and degradation of products, shall not be required unless the importer is a wholesaler. Requires such tests to be conducted by the importer unless a product is a prescription drug subject to the provisions of this Act pertaining to counterfeit-resistant packaging. (Currently either the importer or the manufacturer may conduct such tests).

Eliminates the sunset date current law establishes for the provisions pertaining to the importation of covered products.

Classifies prescription drugs as misbranded if they do not incorporate specified counterfeit-resistant technologies in packaging.

Actions Timeline

- **Sep 8, 2004:** Sponsor introductory remarks on measure. (CR S8932-8933)
- **Feb 27, 2004:** Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 436.
- **Feb 26, 2004:** Introduced in Senate
- **Feb 26, 2004:** Read the first time. Placed on Senate Legislative Calendar under Read the First Time.